Literature DB >> 12719415

Covalent and non-covalent interactions of betaig-h3 with collagen VI. Beta ig-h3 is covalently attached to the amino-terminal region of collagen VI in tissue microfibrils.

Eric Hanssen1, Betty Reinboth, Mark A Gibson.   

Abstract

Transforming growth factor-beta induced gene-h3 (betaig-h3) was found to co-purify with collagen VI microfibrils, extracted from developing fetal ligament, after equilibrium density gradient centrifugation under both nondenaturing and denaturing conditions. Analysis of the collagen VI fraction from the non-denaturing gradient by gel electrophoresis under non-reducing conditions revealed the present of a single high molecular weight band that immunostained for both collagen VI and betaig-h3. When the fraction was analyzed under reducing conditions, collagen VI alpha chains and betaig-h3 were the only species evident. The results indicated that betaig-h3 is associated with collagen VI in tissues by reducible covalent bonding, presumably disulfide bridges. Rotary shadowing and immunogold staining of the collagen VI microfibrils and isolated tetramers indicated that betaig-h3 was specifically and periodically associated with the double-beaded region of many of the microfibrils and that this covalent binding site was located in or near the amino-terminal globular domain of the collagen VI molecule. Using solid phase and co-immunoprecipitation assays, recombinant betaig-h3 was found to bind both native and pepsin-treated collagen VI but not individual pepsin-collagen VI alpha chains. Blocking experiments indicated that the major in vitro betaig-h3 binding site was located in the pepsin-resistant region of collagen VI. In contrast to the tissue situation, the in vitro interaction had the characteristics of a reversible non-covalent interaction, and the Kd was measured as 1.63 x 10(-8) m. Rotary shadowing of immunogold-labeled complexes of recombinant betaig-h3 and pepsin-collagen VI indicated that the in vitro betaig-h3 binding site was located close to the amino-terminal end of the collagen VI triple helix. The evidence indicates that collagen VI may contain distinct covalent and non-covalent binding sites for betaig-h3, although the possibility that both interactions use the same binding region is discussed. Overall the study supports the concept that betaig-h3 is extensively associated with collagen VI in some tissues and that it plays an important modulating role in collagen VI microfibril function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719415     DOI: 10.1074/jbc.M303455200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Crystallization and preliminary crystallographic analysis of the fourth FAS1 domain of human BigH3.

Authors:  Ji-Ho Yoo; EungKweon Kim; Jongsun Kim; Hyun-Soo Cho
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-09-29

2.  Comparative proteomic analysis of normal and collagen IX null mouse cartilage reveals altered extracellular matrix composition and novel components of the collagen IX interactome.

Authors:  Bent Brachvogel; Frank Zaucke; Keyur Dave; Emma L Norris; Jacek Stermann; Münire Dayakli; Manuel Koch; Jeffrey J Gorman; John F Bateman; Richard Wilson
Journal:  J Biol Chem       Date:  2013-03-24       Impact factor: 5.157

Review 3.  Periostin and TGF-β-induced protein: Two peas in a pod?

Authors:  Deane F Mosher; Mats W Johansson; Mary E Gillis; Douglas S Annis
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-08-10       Impact factor: 8.250

4.  Differential expression and processing of transforming growth factor beta induced protein (TGFBIp) in the normal human cornea during postnatal development and aging.

Authors:  Henrik Karring; Kasper Runager; Zuzana Valnickova; Ida B Thøgersen; Torben Møller-Pedersen; Gordon K Klintworth; Jan J Enghild
Journal:  Exp Eye Res       Date:  2009-09-26       Impact factor: 3.467

5.  Proteomic profiling of TGFBI-null mouse corneas reveals only minor changes in matrix composition supportive of TGFBI knockdown as therapy against TGFBI-linked corneal dystrophies.

Authors:  Ebbe Toftgaard Poulsen; Kasper Runager; Nadia Sukusu Nielsen; Marie V Lukassen; Karen Thomsen; Paige Snider; Olga Simmons; Henrik Vorum; Simon J Conway; Jan J Enghild
Journal:  FEBS J       Date:  2017-11-23       Impact factor: 5.542

6.  TGFBI (βIG-H3) is a diabetes-risk gene based on mouse and human genetic studies.

Authors:  Bing Han; Hongyu Luo; John Raelson; Jie Huang; Yun Li; Johanne Tremblay; Bing Hu; Shijie Qi; Jiangping Wu
Journal:  Hum Mol Genet       Date:  2014-04-11       Impact factor: 6.150

7.  Corneal dystrophy-associated R124H mutation disrupts TGFBI interaction with Periostin and causes mislocalization to the lysosome.

Authors:  Bong-Yoon Kim; James A Olzmann; Seung-Il Choi; So Yeon Ahn; Tae-Im Kim; Hyun-Soo Cho; Hwal Suh; Eung Kweon Kim
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

8.  The insoluble TGFBIp fraction of the cornea is covalently linked via a disulfide bond to type XII collagen.

Authors:  Kasper Runager; Gordon K Klintworth; Henrik Karring; Jan J Enghild
Journal:  Biochemistry       Date:  2013-04-15       Impact factor: 3.162

9.  C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells.

Authors:  Rogelio Zamilpa; Rajesha Rupaimoole; Clyde F Phelix; Maria Somaraki-Cormier; William Haskins; Reto Asmis; Richard G LeBaron
Journal:  Matrix Biol       Date:  2009-06-06       Impact factor: 11.583

10.  Evidence against a blood derived origin for transforming growth factor beta induced protein in corneal disorders caused by mutations in the TGFBI gene.

Authors:  Henrik Karring; Zuzana Valnickova; Ida B Thøgersen; Chris J Hedegaard; Torben Møller-Pedersen; Torsten Kristensen; Gordon K Klintworth; Jan J Enghild
Journal:  Mol Vis       Date:  2007-06-27       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.